Samsung announced that its new image post-processing engine (IPE),
S-Vue™ 3.02, recently received FDA clearance. The technology employs an
advanced noise-reduction algorithm that allows devices to produce the
same high-quality image using a fraction of the radiation in pediatric
patients. Image evaluations on devices using S-Vue™ showed they reduced
X-ray dose up to 45% for pediatric abdomen exams, 15.5% for pediatric
chest exams, and up to 27% for pediatric skull exams as compared with
the previous IPE on the same X-ray systems. This data underscores
Samsung’s commitment to minimizing dose exposure, especially in
pediatric patients requiring repeated exposure.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190423005195/en/
Dose Less, Care More: Samsung is committed to delivering superior image quality and optimized dose controls at every stage of the patient journey, starting with the smallest of patients in pediatrics. (Photo: Business Wire)
Samsung’s digital radiography (DR) machines – including GC85A and GM85 –
incorporate Samsung’s S-Vue™ 3.02, which provides spatially adaptive
multi-scale processing and advanced de-noising technology, delivering
quality images with a fraction of the dose.
“Findings of our clinical trial showed that use of Samsung’s S-Vue™ for
pediatric chest images resulted in an overall image quality that was
uncompromised even at a significantly reduced radiation exposure,” said
Susan John, MD, Professor and Chair, Diagnostic and Interventional
Imaging at McGovern Medical School at The University of Texas Health
Science Center at Houston (UT Health). “The reduction in radiation dose
potentially enables repeat radiographs for better follow-up in patients
from infancy into adulthood, while assisting us in confident diagnosis.”
“Constantly working to lower dose exposure is a top priority for
radiologists and healthcare professionals, and Samsung’s ability to
offer dose reduction across its suite of DR machines represents another
breakthrough in medical imaging technology. This new low-dose protocol
is proof that we’re continuing to reduce radiation dose in our products.
We are delighted that we are now able to offer this to the patients who
are most vulnerable,” said David Legg, Vice President, Head of
Ultrasound and Digital Radiography Business, at NeuroLogica, the
healthcare subsidiary of Samsung Electronics.
Samsung is aiming to lower dose exposure in X-ray systems to push ALARA
efforts to the next level for healthcare professionals.
Learn more here: www.samsunghealthcare.com/en/lowdose
*The claim concerning Samsung DR is based on limited phantom and
clinical study results. Only routine PA chest radiography and abdominal
radiography for average adults and pediatric abdominal, chest, skull
radiography were studied, excluding pediatric patients under 1 month old.
About NeuroLogica
NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd.,
develops, manufactures, and markets innovative imaging technologies and
is committed to delivering fast, easy and accurate diagnostic solutions
to healthcare providers. NeuroLogica, the global corporate headquarters
and manufacturer of Samsung computed tomography, is also the US
headquarters for sales, marketing and distribution of all Samsung
digital radiography and ultrasound systems. NeuroLogica’s growing
portfolio of advanced medical technologies are used worldwide in leading
healthcare institutions helping providers enhance patient care, improve
patient satisfaction, and increase workflow efficiency. For more
information, please visit www.NeuroLogica.com.
About Samsung Electronics Co., Ltd.
Samsung
inspires the world and shapes the future with transformative ideas and
technologies. The company is redefining the worlds of TVs, smartphones,
wearable devices, tablets, digital appliances, network systems and
memory, system LSI, foundry and LED solutions. For the latest news,
please visit the Samsung Newsroom at http://news.samsung.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190423005195/en/